Mesothelioma Chemotherapy

Trimodality therapy—using mesothelioma chemotherapy, surgery, and hemithoracic RT—has been used in patients with MPM. Median survival of up to 20 to 29 months has been reported for patients who complete trimodality therapy. Nodal status and response to chemotherapy can affect survival. In patients who do not receive induction chemotherapy before EPP, postoperative sequential chemotherapy with […]